Global Information
회사소개 | 문의 | 비교리스트

세계의 23가 폐렴구균 다당류 백신 시장(2021-2028년)

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1035386
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,230,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,832,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,439,000 PDF & Excel (Enterprise License)


세계의 23가 폐렴구균 다당류 백신 시장(2021-2028년) Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

미국 폐협회에 의하면 폐렴구균성 폐렴은 부비강염, 중이염, 폐렴, 균혈증, 골수염, 패혈증성 관절염, 수막염 등 다양한 질병을 일으킬 가능성이 있는 심각한 질환입니다. 부비강염은 미국에서는 성인 7명 중 1명이 이환하고 있으며, 매년 3,000만명 이상의 사람이 진단을 받고 있다고 여겨지고 있습니다. 또한 면역계는 연령과 함께 자연스럽게 약해지기 때문에 비록 건강하고 활동적이어도 65세 이상은 폐렴구균성 폐렴의 중요한 위험인자이고, COPD, 천식, 심장병, 당뇨병 등의 만성질환 위험 증가로 이어집니다. 따라서 23가 폐렴구균 다당류 백신 수요가 증가하고 있으며, 이것이 예측기간 중 23가 폐렴구균 다당류 백신 시장을 견인할 것으로 생각됩니다.

세계의 23가 폐렴구균 다당류 백신(23-Valent Pneumococcal Polysaccharide Vaccine) 시장에 대해 조사했으며, 시장 개요와 함께 용량 종류별, 연령층별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 세계의 23가 폐렴구균 다당류 백신 시장 - 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 23가 폐렴구균 다당류 백신 시장 - 시장 정의와 개요

제3장 세계의 23가 폐렴구균 다당류 백신 시장 - 주요 요약

  • 용량 종류별 시장 내역
  • 연령층별 시장 내역
  • 지역별 시장 내역

제4장 세계의 23가 폐렴구균 다당류 백신 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 23가 폐렴구균 다당류 백신 시장 - 업계 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 미충족 수요

제6장 세계의 23가 폐렴구균 다당류 백신 시장 - COVID-19 분석

  • 시장에서의 COVID-19 분석
    • COVID-19 이전 시장 시나리오
    • COVID-19 현재 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • COVID-19의 가격 역학
  • 수요와 공급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 23가 폐렴구균 다당류 백신 시장 - 용량 종류별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 매력 지수
  • 일회 투여 바이알
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 프리필드 시린지

제8장 세계의 23가 폐렴구균 다당류 백신 시장 - 연령층별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별
    • 시장 매력 지수
  • 아동(2-10세)
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 성인(10-64세)
  • 고령자(65세 이상)

제9장 세계의 23가 폐렴구균 다당류 백신 시장 - 지역별

  • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년, 지역별
    • 시장 매력 지수
  • 북미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 유럽
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 남미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 아시아태평양
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 중동 및 아프리카
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용량 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 연령층별

제10장 세계의 23가 폐렴구균 다당류 백신 시장 - 경쟁 상황

  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크

제11장 세계의 23가 폐렴구균 다당류 백신 시장 - 기업 개요

  • Merck & Co.
    • 기업 개요
    • 제품 포트폴리오와 개요
    • 주요 하이라이트
    • 재무 개요
  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • AstraZeneca
  • Baxter International Inc.
  • Biogen Inc.
  • Serum Institute of India
  • Eli Lilly and Company
  • Beijing Minhai Biotechnology
  • Pfizer Inc.

제12장 세계의 23가 폐렴구균 다당류 백신 시장 - DataM

  • 부록
  • 당사에 대해
  • 문의
KSM 21.11.16

Market Overview

Pneumococcal is an infectious disease affected by the streptococcus pneumoniae bacteria, which may cause different illnesses such as ear infections, meningitis, and others. Pneumococcal polysaccharide vaccines are advised mostly for adults who suffer from pneumococcal infection.

The global 23-valent pneumococcal polysaccharide vaccine market size was valued US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

Market Dynamics

Growing number of pneumococcal diseases associated with chronic disease patients is expected to drive the market growth.

According to the American Lung Association, Pneumococcal pneumonia is a potentially serious disease that can cause a range of different illnesses, including sinusitis, otitis media, pneumonia, bacteremia, osteomyelitis, septic arthritis and meningitis. Sinusitis affects 1 out of every seven adults in the United States, with more than 30 million individuals diagnosed each year. Moreover, the immune system naturally weakens with age, so even if you're healthy and active, being 65 or older is a key risk factor for pneumococcal pneumonia leading to an increased risk of chronic conditions, including COPD, Asthma, and heart disease Disease and Diabetes. Therefore it has led to an increase in the demand for the 23-Valent pneumococcal polysaccharide vaccine, which is expected to drive the market in the forecast period.

Side effects of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) are expected to hamper the market growth.

According to Merck, PNEUMOVAX 23 is a vaccine that is given as a shot. It helps protect from infection by certain germs or bacteria, which are called pneumococcus. Moreover, Pneumovax 23 vaccine is important for preventing infection in individuals at risk, including those with heart disease, lung disease, liver disease, kidney disease, diabetes, alcoholism, cirrhosis, spleen problems, sickle cell anemia, HIV, certain cancers, adults over 65 years of age. But the vaccine may not protect everyone who gets it, and it will not protect against diseases caused by bacteria types that are not in the vaccine. Besides the benefits of the vaccine, there are few side effects, including pain, warmth, soreness, redness, swelling, and hardening at the injection site, headache, weakness and feeling tired, and muscle pain. Thus, from the above statements, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The coronavirus disease 2019 (COVID-19) pandemic is associated with high morbidity and mortality. Evidence shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is originally transmitted through respiratory droplets from symptomatic, asymptomatic, or pre-symptomatic individuals. Like other respiratory pathogens, such as influenza, where approximately 25% of older patients get secondary bacterial infections, both superinfections and co-infections with SARS-CoV-2 have been reported. However, there is limited data on the frequency of co-infection and superinfections by viral, bacterial, or fungal infections and associated clinical outcomes among patients infected with SARS-CoV-2.

Moreover, the co-infection acts as the recovery of other respiratory pathogens in patients with SARS-CoV-2 infection at the time of a SARS-CoV-2 infection diagnosis and superinfection as the subsequent recovery of other respiratory pathogens during care for SARS-CoV-2 infection. Two previous reviews have examined the prevalence of bacterial and fungal co-infection or superinfection in SARS-CoV-2 infected patients. In addition, prior work suggests outcome differences in patients with co-infections vs. superinfections. For instance, Garcia-Vidal et al. showed that SARS-CoV-2 infected patients with superinfections had a longer hospital stay (LOS) and higher mortality. In contrast, those with co-infections had a higher frequency of admission to the ICU. Diagnostic testing and therapeutic decision-making may be altered by the presence of co-infection or superinfection with SARS-CoV-2 and other respiratory pathogens.

Additionally, the market faces challenges in manufacturing and delivering drugs due to an interrupted supply chain. Providing essential services due to lockdowns has led to reduced supply to the end-users. The pandemic is not likely to have long-term effects on end-users primary growth in the 23-valent pneumococcal polysaccharide vaccine market.

Segment Analysis

Geriatrics (65 years and above) segment is expected to hold the largest market share in this market segment.

The geriatrics (65 years and above) segment is estimated for the largest market share in 2020. The segment growth is attributed to the rise in the geriatric population, rise in the incidence of bacterial infections is expected to boost the market in the forecast period. For instance, according to the Administration for Community Living, published in May 2021, In the U.S., the population age 65 and older numbered 54.1 million in 2019. They represented 16% of the population, more than one in every seven Americans. The number of older Americans has increased by 14.4 million (or 36%) since 2009, compared to 3% for the under-65 population. Between 2009 and 2019, the number of Americans aged 45-64 (who will reach age 65 over the next two decades) increased by 4%, from 80.3 million to 83.3 million. The number of Americans age 60 and older increased by 34%, from 55.7 million to 74.6 million.

Moreover, in 2019, 30 million women and 24.1 million men were age 65 and older. That's 125 women for every 100 men, and people age 65 and older represented 16% of the population in 2019 but are expected to grow to be 21.6% by 2040. Therefore, PPSV23 protects against 23 types of bacteria that cause pneumococcal disease, and it is recommended for all 65 years or older. Most people need only one dose of PPSV23. A second dose of PPSV23, and another type of pneumococcal vaccine called PCV13, are recommended for certain high-risk groups. Furthermore, People 65 years or older should get a dose of PPSV23 even if they had already taken one or more doses of the vaccine before they turned 65. Thus, the segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global 23-valent pneumococcal polysaccharide vaccine market.

North America accounted for the largest revenue share in 2020. The growth is attributed to the high prevalence of bacterial pneumonia, well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players, the largest supplier and consumption market of 23-valent pneumococcal polysaccharide vaccine, are the major factors that the market is expected to boost the forecast period. For instance, according to the American Lung Association, The most common type of bacterial pneumonia is called pneumococcal pneumonia. Pneumococcal pneumonia is caused by the Streptococcus pneumoniae germ that normally lives in the upper respiratory tract. It infects over 900,000 Americans every year. The greatest risk for bacterial pneumonia includes people recovering from surgery, people with respiratory disease or viral infection, and weakened immune systems.

Moreover, it causes more than a million hospitalizations and more than 50,000 deaths each year. Therefore, it has increased the demand for the 23-Valent pneumococcal polysaccharide vaccine, due to which the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

The 23-valent pneumococcal polysaccharide vaccine market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Merck & Co., AstraZeneca, Baxter International Inc., Biogen Inc., Serum Institute of India, Eli Lilly and Company and Beijing Minhai Biotechnology. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the 23-valent pneumococcal polysaccharide vaccine market globally.

Merck & Co.

Overview:

Merck & Co., Inc., outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891. The company develops and produces medicines, vaccines, biological therapies and animal health products. It has multiple blockbuster drugs or products, each with 2020 revenues, including cancer immunotherapy, anti-diabetic medication and vaccines against HPV and chickenpox. Moreover, the company is ranked 69th on the 2021 Fortune 500 and 92nd on the 2021 Forbes Global 2000, both based on 2020 revenues.

Product Portfolio:

Merck & Co. is into continuous manufacturing of products for pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). For instance, PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent).

Why Purchase the Report?

  • Visualize the composition of the global 23-valent pneumococcal polysaccharide vaccine market segmentation by dose type, age-group and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global 23-valent pneumococcal polysaccharide vaccine market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global 23-valent pneumococcal polysaccharide vaccine market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global 23-valent pneumococcal polysaccharide vaccine market report would provide an access to an approx. 47 market data table, 39 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Dose Type

  • Single Dose Vial
  • Pre-Filled Syringe

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Age-Group

  • Children (2-10 years)
  • Adults (10-64 years)
  • Geriatrics (65 years and above)

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Market Definition and Overview

3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Executive Summary

  • 3.1. Market Snippet by Dose Type
  • 3.2. Market Snippet by Age-Group
  • 3.3. Market Snippet by Region

4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing number of pneumococcal diseases associated with chronic disease patients
      • 4.1.1.2. Advancements in the medical technology of vaccines
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of PNEUMOVAX23 (Pneumococcal Vaccine Polyvalent)
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Dose Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 7.1.2. Market Attractiveness Index, By Dose Type Segment
  • 7.2. Single Dose Vial*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Pre-Filled Syringe

8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Age-Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 8.1.2. Market Attractiveness Index, By Age-Group Segment
  • 8.2. Children (2-10 years)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Adults (10-64 years)
  • 8.4. Geriatrics (65 years and above)

9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dose Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group

10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market- Company Profiles

  • 11.1. Merck & Co.
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sanofi S.A.
  • 11.3. GlaxoSmithKline Plc
  • 11.4. AstraZeneca
  • 11.5. Baxter International Inc.
  • 11.6. Biogen Inc.
  • 11.7. Serum Institute of India
  • 11.8. Eli Lilly and Company
  • 11.9. Beijing Minhai Biotechnology
  • 11.10. Pfizer Inc. (*LIST NOT EXHAUSTIVE)

12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market - DataM

  • 12.1. Appendix
  • 12.2. About Us
  • 12.3. Contact Us
Back to Top
전화 문의
F A Q